All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the Lymphoma Coalition.
The Lymphoma Hub uses cookies on this website. They help us give you the best online experience. By continuing to use our website without changing your cookie settings, you agree to our use of cookies in accordance with our updated Cookie Policy
An expert panel hosted by
Customizing first-line BTK inhibitors for CLL
with Gilles Salles, Paolo Ghia, and Francesc Bosch
Wednesday, October 23, 2024
18:30-19:30 BST
This independent educational activity is supported by Pharmacyclics LLC, an AbbVie Company and Janssen Biotech. All content is developed independently by the faculty. The funder is allowed no influence on the content of this activity.
The Lymphoma Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the Lymphoma Hub cannot guarantee the accuracy of translated content. The Lymphoma Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
Glofit-GemOx vs R-GemOx for R/R DLBCL: Results from the STARGLO trial
|
Results from the phase III STARGLO trial (NCT04408638) of glofitamab plus gemcitabine and oxaliplatin (Glofit-GemOx) vs rituximab plus gemcitabine and oxaliplatin (R-GemOx) in patients with relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL) were presented at the European Hematology Association (EHA) 2024 Hybrid Congress by Abramson.1 |
| Key learnings: |
|
The primary endpoint of overall survival (OS) was met. |
|
After a median follow-up of 20.7 months, median OS was 25.5 months vs 12.9 months in the Glofit-GemOx and R-GemOx arms, respectively (hazard ratio [HR], 0.62; p = 0.006). |
|
Glofit-GemOx was associated with improved progression-free survival (PFS) and a higher complete response (CR) rate vs R-GemOx: median PFS was 13.8 months vs 3.6 months (HR, 0.40; p < 0.000001) and the CR rates were 58.5% vs 25.3% (p < 0.0001), respectively. |
|
The safety profile of Glofit-GemOx was consistent with that of the individual agents. |
|
Glofitamab is the first CD20xCD3 bispecific antibody to demonstrate a survival benefit in DLBCL in a randomized phase III trial. |
| The efficacy data from the phase III STARGLO trial and the tolerable safety profile of Glofit-GemOx supports the use of Glofit-GemOx in the treatment of patients with R/R DLBCL. |
- Abramson J. Glofitamab plus gemcitabine and oxaliplatin (GLOFIT-GemOx) for relapsed/refractory (R/R) diffuse large b-cell lymphoma (DLBCL): results of a global randomized phase III trial (STARGLO). Abstract #LB3438. Presented at: European Hematology Association 2024 Hybrid Congress; Jun 13–16; Madrid, ES.
Understanding your specialty helps us to deliver the most relevant and engaging content.
Please spare a moment to share yours.
Please select or type your specialty
Thank youYour opinion matters
14 votes - 23 days left ...
Related articles
Newsletter
Subscribe to get the best content related to lymphoma & CLL delivered to your inbox